Right Turn Show - Decoding the Use of Dapagliflozin and its Combinations with Metformin and Sitagliptin in Specialty Care Settings

Presenting Episode 2 of the Right Turn Show, in this episode, insights from leading experts are explored on the practical application of dapagliflozin and its combinations in speciality settings. The previous episode focused on the consideration of dapagliflozin in specialty care settings. Building on that, this episode delves into the various Fixed Dose Combinations (FDCs) of dapagliflozin.

Dapagliflozin remains a preferred therapy among clinicians for managing Type 2 Diabetes Mellitus (T2DM), while also offering significant benefits in the treatment of heart failure and chronic kidney disease (CKD).

This episode features two distinguished experts, Dr J.C. Mohan, a prominent cardiologist and Chairman of the Institute of Heart & Vascular Diseases at Jaipur Golden Hospital, New Delhi. Prof. Abdul Hamid Zargar, a leading endocrinologist renowned for his expertise in diabetes and endocrine care from Srinagar, Jammu & Kashmir.

In this episode they will address the following key questions:

1) Prioritization of therapies monotherapy, dual FDC, or triple FDC for patients in cardiology and endocrinology settings 

2) Differentiate between using Dapagliflozin monotherapy, Dapagliflozin Sitagliptin dual FDC, and Dapagliflozin Sitagliptin Metformin triple FDC in clinical practice

3) Potential benefits of dapagliflozin, sitagliptin and metformin